Abstract
In spite of the many scientific and clinical debates which have involved adjuvant chemotherapy for high-risk resectable breast cancer, there is general agreement that polydrug regimens, in particular, CMF (cyclophosphamide, methotrexate, and fluorouracil), are effective in improving relapse-free (RFS) and overall survival (OS) rates in premenopausal women (Bonadonna et al. 1977; Bonadonna and Valagussa 1988; Henderson 1987). In this report, we update the results of our two initial prospective randomized trials activated in June 1973 and September 1975 respectively.
Supported in part by Contract NO1-CM-07338 with the Division of Cancer Treatment, National Cancer Institute, National Institutes of Health.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410
Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes: Updated analysis on the disease-free interval, site or relapse and drug tolerance. Cancer 39: 2904–2915
Bonadonna G, Valagussa P (1988) The contribution of medicine to the primary treatment of breast cancer. Cancer Res 48: 2314–2324
Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, Panduro J, Andersen KW on behalf of the Danish Breast Cancer Cooperative Group (1987) Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 5: 1771–1778
Goldie JH, Coldman AJ (1984) The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 44: 3643–3653
Henderson IC (1987) Adjuvant systemic therapy for early breast cancer. Curr Probl Cancer 11: 125–207
Hryniuk WM, Bonadonna G, Valagussa P (1987) The effect of dose intensity in adjuvant chemotherapy. In: Salmon SE (ed) Adjuvant therapy of cancer, vol 5. Grune and Stratton, Orlando, pp 13–23
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Ludwig Breast Cancer Study Group (1985) A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 45: 4454–4459
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1–39
Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U (1983) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2–10
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Bonadonna, G., Valagussa, P., Zambetti, M., Brambilla, C. (1989). The Milan Experience with Adjuvant Chemotherapy in Premenopausal Breast Cancer. In: Senn, HJ., Goldhirsch, A., Gelber, R.D., Osterwalder, B. (eds) Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research, vol 115. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83337-3_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-83337-3_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83339-7
Online ISBN: 978-3-642-83337-3
eBook Packages: Springer Book Archive